You are here

Article Text

Article menu
Download PDFPDF
Poster exhibition Day 1
P1235 Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment
  1. L Lippens1,
  2. M Van Bockstal2,
  3. EA De Jaeghere3,
  4. P Tummers4,
  5. A Makar4,
  6. S De Geyter1,
  7. K Van de Vijver2,
  8. A Hendrix1,
  9. K Vandecasteele5 and
  10. H Denys3
  1. 1Laboratory of Experimental Cancer Research, Department of Human Structure and Repair
  2. 2Pathology, Department of Diagnostic Sciences
  3. 3Medical Oncology, Department of Internal Medicine and Pediatrics
  4. 4Gynecology, Department of Human Structure and Repair
  5. 5Radiation Therapy, Department of Human Structure and Repair, Ghent University Hospital, Ghent, Belgium

Abstract

Introduction/Background We investigated the potential of tumour-infiltrating immune cells in pre- and post-treatment tissue specimens and their changes during treatment as predictive or prognostic biomarkers for cervical cancer patients.

Methodology Cervical cancer patients treated with (chemo)radiotherapy and subsequent surgery were included in the current study. Pre- and post-treatment specimens were retrospectively analysed via immunohistochemistry. Immune cell markers for T cells (CD3, CD4, CD8, and FoxP3), macrophages (CD68 and CD163), and B cells (CD20), as well as interleukin-33 (IL33) and (programmed death-ligand 1 (PD-L1), were analysed. Patients were grouped in the low score or high score group based on the amount of positive cells on immunohistochemistry. Correlations to pathological complete response (pCR), cause-specific survival (CSS), and metastasis development during follow-up were evaluated.

Results In total, 38 patients were included. In analysis of pre-treatment biopsies, significantly more pCR was seen for patients with CD8=CD3, CD8≥CD4, positive IL33 tumour cell (TC) scores, IL33 immune cell (IC)<TC, and PD-L1 TC≥5%. Besides patients with high CD8 scores, also patients with CD8≥CD4, CD163≥CD68, or PD-L1 IC≥5% had better CSS. In analysis of post-treatment specimens, less pCR was observed for patients with high CD8 or CD163 scores. Patients with decreasing CD8 or CD163 scores between pre- and post-treatment samples showed more pCR, whereas those with increasing CD8 or decreasing IL33 IC scores showed a worse CSS. Meanwhile, patients with an increasing CD3 score or stable/increasing PD-L1 IC score showed more metastasis during follow-up (figure 1).

Conclusion The intratumoural immune cell landscape is a tool for prediction of outcome and response to (chemo)radiation.

Disclosure This research was supported by a research grant obtained from Roche. E.A.D. received funding from Fonds Wetenschappelijk Onderzoek (FWO) and K.V. received funding from Stichting tegen Kanker.

Abstract P1235 Figure 1
Abstract P1235 Figure 1

Response, metastasis development, survival, and scores for each patient

https://doi.org/10.1136/ijgc-2019-ESGO.162

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.